(MENAFN- GlobeNewsWire - Nasdaq) The Australia Acute Respiratory Distress Syndrome (ARDS) Market is forecasted to grow from USD 24.82 million in 2024 to USD 44.79 million by 2033, with a CAGR of 6.78%. Key drivers include a rising incidence of respiratory diseases, ICU admissions, and technological innovations. Growing awareness of post-COVID lung damage and an aging population further propel demand. Diagnostic and treatment advancements, such as the VitalFlow ECMO System by Medtronic, enhance patient outcomes. Government investments in healthcare infrastructure also stimulate market growth. Major players include Medtronic, Gilead Sciences, and Pfizer.Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The "Australia Acute Respiratory Distress Syndrome Market Analysis 2025" report has been added to ResearchAndMarkets.com's offering.
The Australia Acute Respiratory Distress Syndrome (ARDS) Market is expected to grow from US$ 24.82 million in 2024 to US$ 44.79 million by 2033, at a compound annual growth rate (CAGR) of 6.78% between 2025 and 2033. Growing incidence of respiratory diseases, increasing admissions to ICUs, and new medical technology are principal drivers for the treatment market for ARDS in Australia.
In Australia, the need for efficient ARDS treatments has increased over the years as a result of an aging population, increasing rates of chronic respiratory conditions, and post-COVID lung damage awareness. There is more hospital equipment with respiratory care technologies such as ventilators and ECMO devices, which help improve treatment success. ARDS care is still of top concern within Australia's health sector, especially in tertiary care centers and respiratory specialty clinics. The seriousness of the condition and possible fatality rates have increased public as well as healthcare industry focus, stimulating ongoing investment in research, diagnosis, and sophisticated treatment techniques in the country.
Growth Drivers in the Australia Acute Respiratory Distress Syndrome Market
Increased Prevalence of Respiratory Diseases
Australia is witnessing a significant surge in chronic respiratory ailments, such as chronic obstructive pulmonary disease (COPD), pneumonia, and severe influenza, which are among the major causes of acute respiratory distress syndrome (ARDS). Also, the long-term complications post-COVID-19 have contributed substantially to the need for inclusive ARDS treatment. The nation's older population, specifically exposed to these conditions, has seen an accelerated rise in hospitalizations and an increased need for advanced respiratory treatment.
Together, these factors are having a strong positive effect on healthcare market expansion, presenting a pressing need for targeted interventions and new forms of treatment in respiratory wellness. In 2022, an estimated 8.5 million (34%) Australians had chronic respiratory diseases, such as asthma and COPD. Approximately 2.8 million (11%) individuals had asthma, and 638,000 (2.5%) had COPD, as per the Australian Institute of Health and Welfare (AIHW).
Advances in Diagnostic and Treatment Technologies
Australia's healthcare system is at the forefront of adopting cutting-edge diagnostic tools and innovative treatment methods for Acute Respiratory Distress Syndrome (ARDS). With the integration of high-resolution imaging techniques, medical professionals can visualize lung pathology with remarkable clarity, allowing for earlier and more accurate diagnoses. Mechanical ventilation has become more sophisticated, providing increasingly subtle modes of support that are tailored to the specific needs of individual patients, and ECMO saves the lives of the most severely ill patients through circulatory and respiratory support. These advances save not only lives but also improve overall outcomes of treatment, having a far-reaching impact on the lives of ARDS patients.
This never-ending quest for innovation propels hospitals and clinics nationwide to invest in state-of-the-art medical equipment, creating a culture of advancement and treatment. Consequently, the ongoing improvement of these practices dramatically raises the quality of patient care and is a key factor in the growth of the healthcare industry in Australia. September 2024, Medtronic introduced the VitalFlow ECMO System, a flexible and modular platform that combines simplicity with performance. The system bridges the gap between intra-hospital transport and bedside care and provides physicians and clinicians with an easier and more intuitive ECMO experience.
Government Healthcare Support and Investments
The Australian government is taking important steps by directing continuous investments into healthcare infrastructure, especially in increasing intensive care unit (ICU) capacities and respiratory care. These investments are important in further developing treatments for Acute Respiratory Distress Syndrome (ARDS).
Through the acquisition of funds for innovative medical research and modernizing hospital facilities, the government is providing a strong readiness to critical care needs. In addition, public health programs prioritize early detection and prompt treatment of ARDS, not only enhancing outcomes for the patient but also strengthening the prospect of the future market. Ensuring increased accessibility of medicine is the key to an improved healthcare system that is more robust eventually, and it benefits the larger population.
Issues in the Australia Acute Respiratory Distress Syndrome Market
High Cost of Advanced Treatment Options
Acute Respiratory Distress Syndrome (ARDS) treatment is usually expensive, involving prolonged Intensive Care Unit (ICU) admissions, mechanical ventilation, and Extracorporeal Membrane Oxygenation (ECMO). Such costs are a huge burden to the public healthcare budget and private health insurance. Expensive treatments may limit some patients' access, especially those from rural settings, and this poses a significant challenge to treating ARDS in an equitable manner across Australia.
Limited Awareness and Delayed Diagnosis
Symptoms of ARDS frequently overlap with those of other respiratory ailments, leading to delays in diagnosis and diagnosis delays, which can cause delays in proper diagnosis and treatment. Limited awareness of the public about ARDS as a disease is also one such factor, and varying diagnostic capabilities across hospitals can cause underdiagnosis or misdiagnosis. These delays can result in deteriorating patient outcomes and the lack of early intervention opportunities, which pose a major hindrance to market growth.
Key Players Analysis (Overviews, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis)
Silence Therapeutics plc. Gilead Sciences Inc. Terumo Corporation Getinge AB Livanova Plc. Medtronic, Inc. Fresenius SE & Nipro Pfizer Inc.
Key Attributes:
CONTACT: CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment